このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Pulsed Radiofrequency Versus 5% Dextrose Injection in Chronic Plantar Fasciitis

2026年6月30日 更新者:Esra Ülgen Kıratlıoğlu、Ankara City Hospital Bilkent

Comparison of Ultrasound-Guided Pulsed Radiofrequency and 5% Dextrose Injection in Patients With Chronic Plantar Fasciitis: A Randomized Controlled Trial

This prospective, two-center, randomized controlled clinical trial aims to compare the effectiveness of ultrasound-guided pulsed radiofrequency and 5% dextrose injection in patients with chronic plantar fasciitis. Eligible participants will be randomized into two parallel groups. One group will receive ultrasound-guided pulsed radiofrequency treatment, and the other group will receive ultrasound-guided 5% dextrose injection using the peppering technique. All participants will receive a home-based plantar fascia stretching exercise program. Outcomes will be assessed at baseline, 3 weeks, 6 weeks, and 12 weeks after treatment. The primary outcome will be pain intensity measured by the Numeric Rating Scale. Secondary outcomes will include foot function, activity-related pain, ankle-hindfoot function, and health-related quality of life.

調査の概要

詳細な説明

Plantar fasciitis is one of the most common causes of chronic heel pain in adults. It may impair walking pattern, daily activities, social life, and work-related functioning. Although conservative treatments are commonly used as first-line therapy, symptoms may become chronic in a considerable proportion of patients.

Dextrose injection is a regenerative injection treatment used in chronic musculoskeletal pain conditions. It is thought to stimulate local tissue healing responses through controlled inflammatory and proliferative mechanisms. Pulsed radiofrequency is a minimally invasive, non-neurodestructive radiofrequency technique used for pain control. Both pulsed radiofrequency and dextrose injection are used in clinical practice for resistant chronic plantar fasciitis; however, comparative data between these two approaches are limited.

This study will be conducted as a prospective, two-center, two-arm, parallel-group randomized controlled trial in the Physical Medicine and Rehabilitation clinics of Ankara Bilkent City Hospital and Adana City Hospital. Participants with chronic plantar fasciitis will be randomized in a 1:1 ratio using the sealed-envelope method. The investigator responsible for randomization will know the allocation, while the outcomes assessor will be blinded to treatment allocation. Blinding of the interventionists will not be possible due to the nature of the procedures.

Participants in the pulsed radiofrequency group will receive ultrasound-guided pulsed radiofrequency treatment at baseline. Participants in the 5% dextrose group will receive ultrasound-guided 5% dextrose injection around the medial calcaneal insertion of the plantar fascia using the peppering technique, with 0.1-0.2 mL administered at each entry point. Dextrose injections will be performed in three sessions at 3-week intervals.

All participants will receive a home-based plantar fascia stretching exercise program. Exercises will be demonstrated by a physiotherapist, and participants will be instructed to perform the exercises twice daily for 12 weeks. Participants will be monitored for possible adverse events or complications for at least 30 minutes after the procedure. Clinical outcomes will be assessed at baseline, 3 weeks, 6 weeks, and 12 weeks.

研究の種類

介入

入学 (推定)

50

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Esra Ülgen Kıratlıoğlu, MD
  • 電話番号:+905079614194
  • メール:esraulgen@gmail.com

研究場所

      • Ankara、トルコ(Türkiye)
        • 募集
        • Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Diagnosis of chronic plantar fasciitis based on medical history and physical examination
  • Heel pain resistant to conservative treatment for at least 12 weeks
  • Age between 18 and 70 years
  • Willingness to participate in the study and provide written informed consent

Exclusion Criteria:

  • Congenital or acquired disease that may impair or prevent foot function, such as rheumatoid arthritis, hemiplegia, congenital foot deformity, traumatic foot or leg amputation, or fracture sequelae
  • Local infection or skin disease at the treatment site
  • Bleeding disorder or use of anticoagulant medication within the last week
  • Disease causing mental dysfunction, such as uncontrolled Parkinson disease or Alzheimer disease
  • Previous surgery for plantar fasciitis
  • Refusal to participate in the study or inability to provide informed consent
  • Failure to attend follow-up visits after treatment
  • Request to withdraw from the study
  • Pregnancy or suspected pregnancy
  • Presence of a cardiac pacemaker
  • History of epilepsy
  • Active or previous malignancy
  • Rheumatologic disease

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Ultrasound-Guided Pulsed Radiofrequency Treatment
Participants in this group will receive ultrasound-guided pulsed radiofrequency treatment at baseline. Clinical follow-up assessments will be performed at 3 weeks, 6 weeks, and 12 weeks. All participants will also receive a home-based plantar fascia stretching exercise program.
Ultrasound-guided pulsed radiofrequency treatment will be applied for chronic plantar fasciitis. Participants will be monitored for at least 30 minutes after the procedure for possible adverse events or complications.
アクティブコンパレータ:Ultrasound-Guided 5% Dextrose Injection
Ultrasound-guided pulsed radiofrequency treatment will be applied for chronic plantar fasciitis. Participants will be monitored for at least 30 minutes after the procedure for possible adverse events or complications.
Ultrasound-guided 5% dextrose injection will be applied around the medial calcaneal insertion of the plantar fascia using the peppering technique, with 0.1-0.2 mL administered at each entry point. The treatment will consist of three sessions performed at 3-week intervals.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Heel Pain Intensity Assessed by Numeric Rating Scale
時間枠:Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Heel pain intensity will be assessed using the Numeric Rating Scale. Resting pain, pain during plantar fascia stretching, and pain with pressure will be evaluated on an 11-point scale from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.
Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Activity-Related Pain Assessed by the Roles and Maudsley Score
時間枠:Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Activity-related heel pain and functional status will be assessed using the Roles and Maudsley Score. The score ranges from 1 to 4, with lower scores indicating better clinical status and higher scores indicating worse pain and functional limitation.
Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Change in Foot Function Assessed by the Foot Function Index
時間枠:Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Foot-related pain, disability, and activity limitation will be assessed using the Foot Function Index. The scale includes pain, disability, and activity limitation subscales. Scores are converted to a 0-100 scale, with higher scores indicating greater pain, disability, and activity limitation.
Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Change in Ankle-Hindfoot Function Assessed by the American Orthopaedic Foot and Ankle Society Score
時間枠:Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Ankle-hindfoot function will be assessed using the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Score. The score evaluates pain, function, and alignment. The total score ranges from 0 to 100, with higher scores indicating better ankle-hindfoot function.
Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Change in Health-Related Quality of Life Assessed by the Nottingham Health Profile
時間枠:Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Health-related quality of life will be assessed using the Nottingham Health Profile. The questionnaire includes six domains: energy level, pain, emotional reactions, sleep, social isolation, and physical activity. The total score ranges from 0 to 600, with higher scores indicating worse perceived health status.
Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月1日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2027年1月1日

試験登録日

最初に提出

2026年6月30日

QC基準を満たした最初の提出物

2026年6月30日

最初の投稿 (実際)

2026年7月7日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月7日

QC基準を満たした最後の更新が送信されました

2026年6月30日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する